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Abstract
Background: Cystic ﬁ  brosis patients require daily airway clear-
ance therapies. The primary objective of this study was to compare 
the short-term efﬁ  cacy of high-frequency chest compression and 
positive expiratory pressure mask on expectorated sputum, pulmo-
nary function, and oxygen saturation in patients with CF hospital-
ized for an acute pulmonary exacerbation.
Methods: A controlled randomized cross-over trial with 24 hours 
between treatments was used. Thirty-four CF patients (26 ± 6.5 
years) were included in the study. Before and 30 minutes after each 
treatment were recorded: pulmonary function testing, oxygen satu-
ration, and perceived dyspnea. Preference for the two devices was 
assessed.
Results: No statistically signiﬁ  cant difference between high-fre-
quency chest compression and positive expiratory pressure mask 
was found in sputum production and in lung function testing. A re-
duction in SpO2 was found after positive expiratory pressure mask 
(98 ± 1.0% versus 97 ± 1.2%; P < 0.001). Both treatments induced 
a statistically signiﬁ  cant increase in Borg scale for dyspnea with-
out differences between them. Patients reported greater satisfaction 
with positive expiratory pressure mask than with high-frequency 
chest compression (P < 0.001).
Conclusions: High-frequency chest compression and positive ex-
piratory pressure mask have comparable short-term effects on ex-
pectorated sputum and lung function. Although positive expiratory 
pressure mask was associated with a lower SpO2, it was better toler-
ated than high-frequency chest compression.
Keywords: Airway clearance therapies; High-frequency chest 
compression; Sputum; Cystic ﬁ  brosis
Introduction
In cystic ﬁ  brosis (CF) mucociliary clearance is impaired, 
and infected airway secretions gradually cause lung tissue 
destruction. As a result, peripheral airways tend to collapse 
leading to trapping air, mucus obstruction, and chronic pul-
monary infections [1]. Airway clearance therapies (ACTs) 
are one of the cornerstones of CF treatment. Main goal of the 
ACTs is to improve ventilation and enhance airway clear-
ance through the mobilization and expectoration of mucus. 
Over the last years new ACTs has been developed in the at-
tempt to provide more independence, better quality of life 
and increased compliance through a more comfortable and 
less time consuming technique [2].
High-frequency chest compression (HFCC), an oscilla-
tory device, is a self-administered chest physiotherapy that 
with an inﬂ  atable compressive jacket generates airways vi-
brations, increases airﬂ  ow, and mobilizes mucus. Though 
HFCC was ﬁ  rstly used in 1990 showing greater results than 
conventional physiotherapy in mucus clearance [3], litera-
ture still shows conﬂ  icting results about the effectiveness of 
this therapy.
Compared with conventional physiotherapy (i.e. postur-
al drainage and percussion, PD&P), Kluft et al reported that 
HFCC produced a greater amount of sputum over a six-day 
period [4], and Warwick ﬁ  rst demonstrated a positive long-
term effect of HFCC on FEV1 (forced expiratory volume in 
1 second) and FVC (forced vital capacity) [5]. Other stud-
ies found no difference in pulmonary function [6-8], spu-
tum production [6, 7, 9], and in oxygen saturation during 
or following treatments [8]. If compared with active cycle 
of breathing techniques, HFCC resulted less effective in im-
proving lung volumes and mucus expectoration [10] 
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Patients preference, a critical determinant of ACTs ad-
herence [11], was discussed by Braggion and Varekojis, 
without statistical evidence [6, 9], and by Arens who report-
ed greater satisfaction with HFCC [8]. The latest study com-
paring HFCC, postural drainage and Flutter device, although 
early interrupted for high dropout rate, showed that patients 
were more satisﬁ  ed with oscillating devices [12].
A recent review concluded that oscillating devices are 
not superior, in terms of effectiveness and acceptability, to 
any other forms of physiotherapy techniques [13].
A more common airway clearance device is the posi-
tive expiratory pressure (PEP) mask that, increasing air ﬂ  ow 
to small peripheral airways, is thought to have beneﬁ  cial 
effects on sputum production [14]. To date, in CF patients 
HFCC was compared to PEP in only three trials [6, 15, 16]. 
Two of them found no statistical difference in sputum pro-
duction [6] and lung function with both devices [6, 16]; the 
more recent trial by Osman et al reported a statistically sig-
niﬁ  cant greater volume of expectoration by usual ACTs but 
no difference in lung volumes [15]. Notably, the results from 
the latter study came from a comparison between HFCC and 
usual ACTs including, not only PEP, but also active cycle of 
breathing techniques with postural drainage and percussion, 
autogenic drainage, and Flutter device.
The aim of the present study was to compare the short-
term efﬁ  cacy, assessed by sputum production, of HFCC and 
PEP in hospitalized adult patients with mild to moderate CF 
lung disease. Secondary outcomes included pulmonary func-
tion tests, and oxygen saturation before and after each airway 
clearance treatment, adverse effects and patient preference.
Materials and Methods
Subjects
Participants were current patients of the Cystic Fibrosis Unit 
of Parma University Hospital, admitted to ward for manage-
ment of an acute exacerbation of respiratory symptoms. The 
inclusion criteria were a conﬁ  rmed diagnosis of CF, age > 18 
years, mild to moderate lung function impairment (FEV1 > 
60%), chronic infection by Pseudomonas aeruginosa, and an 
infective pulmonary exacerbation as deﬁ  ned by the follow-
ing symptoms: increased cough, volume and purulence of 
sputum, fatigue, dyspnoea, decrease in pulmonary function, 
and weigh loss [17]. The patients were treated with intrave-
nous antibiotics (combination of β-lattamic plus aminogly-
coside) for at least 15 days. In addition, routine medication 
was continued throughout the study.
Exclusion criteria were patients on steroid therapy, pa-
tients awaiting for lung transplant, affected by concomitant 
malignancies, haemoptysis, and rib fractures, or pregnancy. 
Informed consent was obtained from all individuals and the 
study was approved by the Ethical Committee of the Univer-
sity of Parma.
Enrolled patients routinely used PEP mask therapy three 
times daily. Before starting the study each patient was famil-
iarized with HFCC through a certiﬁ  ed respiratory therapist 
who explained how the device operated.
Study design
A randomized cross-over trial with 24 hours between treat-
ments was used to compare HFCC and PEP mask. Patients 
were admitted on day 0 and, after clinical and functional 
evaluation, underwent either PEP mask therapy on day 1 and 
HFCC treatment on day 2 or vice-versa. Subjects were as-
signed to one of the two treatments by numbering them con-
secutively: odd-numbered subjects were assigned to perform 
HFCC on day 1 and PEP therapy on day 2; even-numbered 
subjects did the opposite. All study sections were at morning, 
between 8.00 h a.m. and 10.00 h a.m.; each airway clearance 
treatment session lasted 30 minutes and was assisted by the 
same physiotherapist.
On each study section, immediately before and 30 min-
utes after each treatment, pulmonary function testing, trans-
cutaneous pulsed arterial oxygen saturation (SpO2, %), and 
perceived dyspnea ratings were recorded. During each treat-
ment session and over 30 minutes the amount (mL) of spu-
tum was collected and measured with a burette. An indepen-
dent observer, blind to the method of airway clearance used, 
performed the spirometry and weighed the sputum. At the 
end of the trial patients were asked if they felt comfortable 
with the two devices answering to a Yes/No question.
High-frequency chest compression (HFCC)
HFCC is a portable mechanical method of self-administered 
chest physiotherapy. HFCC was delivered by a pneumatic 
vest (The Vest Airway Clearance System Model 4 by Hill-
Rom®, St. Paul, MN, US), appropriately sized, that sur-
rounded the thorax of the patient. Vest was connected by two 
tubes to the air-pulse generator and inﬂ  ated by a constant 
positive pressure with a 15-20 Hz frequency of air pressure 
oscillations. The pulse pressure (ranging 6-10 on the 1-10 
Vest’s scale) was set according to individual patient’s re-
ported comfort. Subjects remained in the upright sitting po-
sition throughout the 30 minutes treatment session. During 
the HFCC patients were invited to huff and to cough actively 
(ranging 3-5 times) as to expectorate dislodged bronchial se-
cretions.
Positive expiratory pressure (PEP)
PEP mask (Astra Tech AB, Molndal, Sweden) has a one-
way valve to which an expiratory oriﬁ  ce resistor is attached. 
When the patient exhales trough the resistor a positive pres-
sure is generated in the airways (10-20 cm H2O) and col-
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lapsed lung are re-inﬂ  ated raising the functional residual 
capacity. According to the guidelines, the patients, placed in 
a sitting position, were instructed to hold tightly the mask 
over the mouth and the nose and were invited to breath using 
slightly active breaths for 30 minutes. Each treatment con-
sisted of 15 breaths approximately followed by more cycles 
of forced expiration (huff). The number of cycles within a 
treatment session was adapted to individual comfort [18].
Pulmonary function testing and perceived dyspnoea rat-
ings
Spirometry was performed with a computerized spirometer 
(VMAX22 PFT Sensormedics, Yorba Linda, CA, US) ac-
cording to the international standards [19]. FEV1 (%), forced 
expiratory ﬂ  ow 25-75 (FEF25-75, %), and FVC were recorded 
and expressed as percent of predicted value. SpO2 was mea-
sured by a ﬁ  ngertip pulse oximeter (Nellcor P200, Puritan 
Bennett LLC, Boulder, CO, US).
Perceived dyspnoea ratings were obtained by using a 
modiﬁ  ed Borg scale labeled from 0 (no symptoms) to 10 
(maximum bearable) [20].
Statistical analysis
Data were expressed as mean ± SD or percentage, as appro-
priate. Paired t-test or Chi Square analysis was used for com-
parisons, when appropriate. A P value < 0.05 was considered 
as statistically signiﬁ  cant. All analyses were conducted using 
SPSS Statistics 16.0 (IBM®).
Results
Thirty-six CF patients were enrolled. Thirty four of 36 (20 
females) completed the study, two  patients withdrew from 
the study because of discomfort with HFCC device. In pa-
tients who completed the study, both PEP and HFCC tech-
niques have not been associated with statistically signiﬁ  cant 
side effects. Demographics and baseline characteristics of 
the 34 patients are shown in Table 1.
FEV1, FEF25-75 and FVC measured before and after PEP 
Demographics and baseline characteristics value
Age (year) 26 ± 6.5
Gender (M / F) 14 / 20
BMI (kg/m2) 19.72 ± 6.35
SpO2 (%) 97.7 ± 1.4
FEV1 (% pred) 67 ± 17
Table 1. Demographics of Enrolled Participants
Table 2. Lung Function Values: Before (Pre) and After (Post) PEP and HFCC Treatments
BMI: body mass index; SpO2: transcutaneous pulsed arterial oxygen saturation; FEV1: 
forced expiratory volume in 1 second. Data are presented as mean ± SD or ratio as 
appropriate.
FEV1: forced expiratory volume in 1 second; FEF25-75: forced expiratory ﬂ  ow 25 - 75%; FVC, forced vital capacity. *P < 0.001. 
No statistically signiﬁ  cant difference was found in spirometric values before and after both treatments. A statistically signiﬁ  cant 
decrease in SpO2 values was found after PEP treatment.
Device
FEV1
(% predicted)
FEF25-75 (%) FVC (%) SpO2 (%)
pre post pre post pre post pre post
HFCC 67 ± 17 66 ± 17 34 ± 21 33 ± 21 88 ± 17 87 ± 16 97 ± 1.6 97 ± 1.2
PEP 67 ± 16 67 ± 16 34 ± 20 34 ± 19 88 ± 15 87 ± 15 98 ± 1.0 97 ± 1.2*
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mask and HFCC treatment session are reported in Table 2. 
No statistically signiﬁ  cant difference was found after both 
treatments. As compared to baseline values, small but statis-
tically signiﬁ  cant decrease in SpO2 values was found after 
PEP treatment (98 ± 1.0% versus 97 ± 1.2%; P < 0.001), 
but not after HFCC treatment (97 ± 1.6% versus 97 ± 1.2%) 
(Table 2).
The average amount of sputum expectorated after PEP 
(8.8 ± 8.8 mL) and after HFCC (7.5 ± 8.9 mL) did not sig-
niﬁ  cantly differ (Fig, 1). Both treatments induced a statisti-
cally signiﬁ  cant increase in Borg scale for dyspnea without 
differences between them (Table 3).
Forty-one per cent of the patients expressed no prefer-
ence for the devices reporting that they found comfortable 
both techniques, 50% preferred PEP therapy, and 9% HFCC 
(P < 0.001).
Discussion
  
The present study showed that in CF patients, hospitalized 
for pulmonary exacerbation, both PEP and HFCC had com-
parable short-term effect on sputum production and lung 
function. A small but statistically signiﬁ  cant reduction in 
oxygen saturation was found following PEP therapy; but not 
after HFCC. PEP therapy was much preferred than HFCC.
Our study conﬁ  rmed the ﬁ  ndings by previous reports that 
found no statistically signiﬁ  cant differences between baseline 
and after intervention values with either HFCC or PEP, both 
in sputum production and pulmonary function measures [6, 
7]. By contrast, Kluft et al reported a greater effect of HFCC 
on sputum production compared to other conventional tech-
niques [4]. However, it is of note that in that study a nebulised 
saline was administered throughout the treatment to prevent 
airway drying. Taken together these ﬁ  ndings suggest that the 
nebulised saline solution could magnify the effect of HFCC. 
The absence of a statistically signiﬁ  cant modiﬁ  cation in lung 
volumes suggests that spirometry may be inadequate to detect 
the short-term effects of ACTs.
We found a small but statistically signiﬁ  cant reduction 
in oxygen saturation when patients underwent PEP therapy. 
But the results showed that this ﬁ  nding was not due to a 
greater mucus mobilization. An opposite result was reported 
in the study by Darbee et al, where oxygen saturation in-
creased during PEP and decreased during HFCC. These 
modiﬁ  cations were not sustained after treatment [16]. The 
discrepancy between our and Darbee’s results can be ex-
plained by differences in the study protocol. In our study, ox-
ygen saturation was recorded 30 minutes after therapy, while 
in the study by Darbee et al it was recorded during therapy 
Table 3. Borg Dyspnea Scale Before (Pre) and After (Post) PEP and HFCC 
Treatments
Both treatments induced a statistically signiﬁ  cant increase in Borg scale for dyspnea, 
without differences between them.
Figure 1. Mean and individual values of sputum expectoration after PEP and HFCC 
in 34 CF patients.
Pre Post P value
HFCC 0.7 ± 0.9 1.5 ± 1.7 < 0.01
PEP 0.9 ± 1.2 1.6 ± 1.6 < 0.001
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[16]. Importantly, ours and Darbee’s results may suggest to 
monitor oxygen saturation during and after airway clearance 
treatments, mainly in CF patients with severe lung disease 
where SpO2 desaturation may be greater and more clinically 
signiﬁ  cant.
A recognized positive feature of high-frequency chest 
wall oscillations is that it is self-administered and do not 
require the patient to change positions [4]; accordingly, 
HFCC might preserve independence and it may be useful 
in fatigue patients who cannot tolerate additional respiratory 
work. However, in spite of that and by contrast with previous 
studies, reporting greater satisfaction and compliance with 
oscillatory devices compared to conventional chest physio-
therapy [8, 12], our patients expressed more satisfaction with 
PEP therapy than HFCC. Furthermore, two out of 36 patients 
withdrew from the study because of discomfort with HFCC 
device. It is conceivable that the preference for HFCC dem-
onstrated by the previous studies may have been inﬂ  uenced 
by the study protocol modalities. Notably, in these studies 
physiotherapy was self-managed, performed at home, and 
the compliance to the treatment was not constantly assured 
by a physiotherapist.
We are aware of the limitations of our study. Firstly, we 
assessed the short-term effect of the two airway clearance 
devices and we cannot draw any conclusion about their long-
term effects. To date, few trials have compared the potential 
beneﬁ  ts of HFCC with other forms of airway clearance and 
the studies were mostly 1 or 2 days long. Recently, Sontag et 
al [12] started a 3 years-longitudinal trial to compare PD&D, 
HFCC and Flutter device but they ended early the study be-
cause of the high rate of withdrawal. Secondly, in the pres-
ent study we considered fresh sputum, as outcome measure. 
Scherer et al [7] reported that evaluating ACTs efﬁ  cacy 
through fresh sputum weight might be inaccurate because of 
the contaminations of lower airways secretions with saliva, 
due to its high water content. However, no difference has 
been found between dried and fresh sputum, when consid-
ered as outcome measures to assess the efﬁ  cacy of different 
airway clearance devices [4].
In conclusion, our study showed that HFCC was compa-
rable to PEP in terms of sputum production and lung func-
tion effects, but not in terms of acceptability. To date no stud-
ies have clearly demonstrated the optimal airway clearance, 
likely due to different patients features, such as age, compli-
ance, concomitant disease, and severity of lung involvement 
by CF [21]. Thus, airway clearance treatment should be indi-
vidualized, and its efﬁ  cacy periodically reassessed evaluat-
ing  patient preference and objective measures, such as lung 
function test or exacerbation rate.
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